8-K: Coherus BioSciences Secures $38.7 Million Loan and Sells Revenue Rights for $37.5 Million

Coherus BioSciences has entered into a new $38.7 million term loan facility and sold revenue participation rights for $37.5 million to refinance existing debt and bolster its financial position.

Summary

• Coherus BioSciences secured a senior secured term loan of up to $38.7 million on May 8, 2024.
• The loan, provided by Ankura Trust Company and other lenders, matures on May 8, 2029, and carries an interest rate of 8.00% per annum plus a three-month SOFR rate.
• The loan proceeds were used to fully repay the company's previous $75 million debt with BioPharma Credit, PLC.
• Coherus also entered into a revenue participation right purchase and sale agreement, selling a mid-single digit percentage of U.S. net sales of UDENYCA and LOQTORZI for $37.5 million.
• The purchaser's right to receive revenue payments will terminate once they receive 2.25 times the purchase price, or the company can buy out the rights at the same multiple.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company has taken on new debt, it has also secured a significant cash infusion. The high interest rate and giving up future revenue are negatives, but the refinancing and cash injection are positives.

Positives

• The new loan refinances existing debt, potentially improving the company's financial flexibility.
• The sale of revenue rights provides an immediate cash infusion of $37.5 million.
• The company has the option to buy back the revenue rights in the future.

Negatives

• The new loan carries an interest rate of 8.00% plus SOFR, which could be a significant expense.
• The company has given up a portion of future revenue from UDENYCA and LOQTORZI.
• The loan is secured by substantially all of the company's assets, including intellectual property.

Risks

• The company must maintain certain levels of cash and cash equivalents as part of the loan agreement.
• Failure to meet loan covenants could trigger an event of default, leading to higher interest rates and potential penalties.
• The company is now obligated to make quarterly interest payments on the new loan.
• The company has given up a portion of future revenue from UDENYCA and LOQTORZI which could impact future profitability.

Future Outlook

The company will file the full terms of the loan and revenue agreements with the SEC as exhibits to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.

Industry Context

This announcement reflects a common strategy for biotech companies to manage debt and raise capital through various financial instruments. The sale of revenue rights is a way to monetize future sales without diluting equity.

Comparison to Industry Standards

• The interest rate of 8.00% plus SOFR is relatively high, suggesting Coherus may have limited access to lower-cost capital, which is not uncommon for companies with limited profitability.
• The sale of revenue rights is a common practice in the biotech industry, similar to royalty monetization deals seen with companies like Royalty Pharma and Ligand Pharmaceuticals.
• The multiple of 2.25 times the purchase price for the revenue rights is within the typical range for such agreements, but the specific terms will depend on the perceived risk and potential of the underlying products.

Stakeholder Impact

• Shareholders may view the refinancing and cash infusion positively, but the high interest rate and sale of revenue rights could be a concern.
• Creditors now include Ankura Trust Company and the new lenders, while the previous creditors have been repaid.
• Employees may not be directly impacted by these transactions, but the company's financial stability is important for job security.
• Customers and suppliers are unlikely to be directly impacted by these financial transactions.

Next Steps

• The company will file the full terms of the loan and revenue agreements with the SEC.
• The company will make quarterly interest payments on the new loan.
• The company will report on the impact of these transactions in future financial reports.

Key Dates

Keywords

Term Loan, Revenue Participation, Debt Refinancing, UDENYCA, LOQTORZI, BioPharma Credit, Ankura Trust Company, Financial Agreement